Literature DB >> 24643839

[Pharmacokinetic and pharmacodynamic aspects in antibiotic treatment].

R Bellmann1.   

Abstract

Severe sepsis and septic shock have a high mortality and, therefore require fast and effective antibiotic treatment with low toxicity. Because of sepsis-induced pathophysiological changes, pharmacokinetics of antimicrobial agents can be altered. Particularly water-soluble drugs display an enhanced volume of distribution during early sepsis. Therefore high loading doses are necessary. Renal clearance can also be increased at this time. Later on, organ damage frequently occurs resulting in delayed drug elimination which requires further dose adjustment. The different classes of antibiotics differ in their relevant pharmacokinetic-pharmacodynamic target parameters. Thus, the efficacy of an antimicrobial agent can depend on its concentration, on the exposure time, and on the total exposure as expressed by the area under the time-concentration curve. During treatment with time-dependent antibiotics (e.g. β-lactams), their concentration should be maintained above the minimal inhibitory concentration (MIC) warranting more frequent administration or continuous infusion. For concentration dependent agents (e.g. aminoglycosides), the single dose is pivotal, whereas the dosage interval can be extended. Drug-drug interactions involving antibiotics are mainly caused by inhibition of their metabolism, particularly of cytochrome P 450 iso-enzymes, or by additive toxic effects. They can result in severe complications such as renal failure or ventricular arrhythmias. Conversely, enzyme induction may lead to subtherapeutic drug levels. When continuous renal replacement therapy is required, the dosage of antibiotics has to be adapted according to the results of respective pharmacokinetic studies.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24643839     DOI: 10.1007/s00063-013-0308-1

Source DB:  PubMed          Journal:  Med Klin Intensivmed Notfmed        ISSN: 2193-6218            Impact factor:   0.840


  29 in total

1.  Clearance of ceftazidime during continuous venovenous haemofiltration in critically ill patients.

Authors:  Friederike Traunmüller; Peter Schenk; Christoph Mittermeyer; Renate Thalhammer-Scherrer; Klaus Ratheiser; Florian Thalhammer
Journal:  J Antimicrob Chemother       Date:  2002-01       Impact factor: 5.790

Review 2.  Antimicrobial therapy in critically ill patients: a review of pathophysiological conditions responsible for altered disposition and pharmacokinetic variability.

Authors:  Federico Pea; Pierluigi Viale; Mario Furlanut
Journal:  Clin Pharmacokinet       Date:  2005       Impact factor: 6.447

3.  Elimination of the piperacillin/tazobactam combination during continuous venovenous haemofiltration and haemodiafiltration in patients with acute renal failure.

Authors:  M Valtonen; E Tiula; O Takkunen; J T Backman; P J Neuvonen
Journal:  J Antimicrob Chemother       Date:  2001-12       Impact factor: 5.790

4.  Single-dose pharmacokinetics of fosfomycin during continuous venovenous haemofiltration.

Authors:  Rainer Gattringer; Brigitte Meyer; Gottfried Heinz; Claudia Guttmann; Markus Zeitlinger; Christian Joukhadar; Peter Dittrich; Florian Thalhammer
Journal:  J Antimicrob Chemother       Date:  2006-06-16       Impact factor: 5.790

5.  Vancomycin clearance during continuous venovenous haemofiltration in critically ill patients.

Authors:  F T Boereboom; F F Ververs; P J Blankestijn; T J Savelkoul; A van Dijk
Journal:  Intensive Care Med       Date:  1999-10       Impact factor: 17.440

6.  Fluconazole dosing in continuous veno-venous haemofiltration (CVVHF): need for a high daily dose of 800 mg.

Authors:  Raoul Bergner; Martin Hoffmann; Klaus-Dieter Riedel; Gerd Mikus; Dirk M Henrich; Walter E Haefeli; Michael Uppenkamp; Ingeborg Walter-Sack
Journal:  Nephrol Dial Transplant       Date:  2005-11-25       Impact factor: 5.992

7.  Trimethoprim/Sulfamethoxazole pharmacokinetics in two patients undergoing continuous venovenous hemodiafiltration.

Authors:  Ivanka Curkovic; Beatrice Lüthi; Daniel Franzen; Alessandro Ceschi; Alain Rudiger; Natascia Corti
Journal:  Ann Pharmacother       Date:  2010-09-07       Impact factor: 3.154

8.  Amphotericin B lipid formulations in critically ill patients on continuous veno-venous haemofiltration.

Authors:  Romuald Bellmann; Petra Egger; Walter Gritsch; Rosa Bellmann-Weiler; Michael Joannidis; Nicole Kaneider; Stefan Dunzendorfer; Christian J Wiedermann
Journal:  J Antimicrob Chemother       Date:  2003-03       Impact factor: 5.790

9.  Pharmacokinetics of voriconazole during continuous venovenous haemodiafiltration.

Authors:  Valentin Fuhrmann; Peter Schenk; Walter Jaeger; Michaela Miksits; Nikolaus Kneidinger; Joanna Warszawska; Ulrike Holzinger; Reinhard Kitzberger; Florian Thalhammer
Journal:  J Antimicrob Chemother       Date:  2007-09-13       Impact factor: 5.790

Review 10.  Antimicrobial drug interactions in the critically ill patients.

Authors:  Jose M Pereira; Jose A Paiva
Journal:  Curr Clin Pharmacol       Date:  2013-02-01
View more
  2 in total

Review 1.  [First-line anti-infective treatment in sepsis].

Authors:  H Burgmann
Journal:  Med Klin Intensivmed Notfmed       Date:  2014-10-26       Impact factor: 0.840

Review 2.  [Personalised pharmacotherapy in intensive care unit patients].

Authors:  R Bellmann
Journal:  Med Klin Intensivmed Notfmed       Date:  2017-05-02       Impact factor: 0.840

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.